Nanjing To Invest RMB 10 Billion Over Next Three Years To Establish 'Drug Valley'
This article was originally published in PharmAsia News
At the 2009 International Pharmaceutical Research and Cooperation Conference organized by Nanjing Municipal Government and Nanjing Commerce and the Trade Promotion Commission, it was revealed that the city will prioritize the financial support of establishing key biopharmaceutical companies' core technologies and platforms. To forge a world-class "drug valley," Nanjing will make efforts to jointly channel RMB 10 billion ($1.5 billion) on four levels - nation, province, city and district - from 2009 to 2012. This will lead corporations and various private capitals to invest more than RMB 100 billion. At the end of 2008, Nanjing housed more than 100 biopharmaceutical R&D and manufacturing companies, which formed the beginnings of an industry cluster. (Click here for more - Chinese Language)
You may also be interested in...
Cipla gets US FDA go-ahead earlier than anticipated for first generic of Merck’s Proventil, setting the stage for increased competition in the albuterol segment, where demand is up amid the coronavirus pandemic.
The entry of India’s state-owned Indian Immunologicals and partner Griffith University in the COVID-19 vaccine race could potentially disrupt pricing dynamics. The alliance is developing a live-attenuated, single dose vaccine, which it hopes will be ready for launch in 18-24 months.
Shortly after wrapping up a Phase III trial for its proposed generic Advair Diskus product in the US, Cipla has won FDA approval for the first generic Proventil HFA product, as it continues to build up steam in the US respiratory market.